Decoding Drug Safety: What You Need to Know About Pharmacovigilance
"A look at how India is strengthening its drug monitoring systems to protect public health."
In today's world, ensuring the safety of medications is a top priority. The concept of pharmacovigilance, which involves monitoring and preventing adverse effects of drugs, has become increasingly important. This article will explore the current state of pharmacovigilance, particularly in the context of India's healthcare system.
Pharmacovigilance, as defined by the World Health Organization (WHO), encompasses the science and activities related to detecting, assessing, understanding, and preventing adverse effects of drugs or any other drug-related problems. It begins during clinical trials and continues throughout a drug's lifecycle. A key focus is on adverse drug reactions (ADRs), which are unintended and harmful responses to a drug at normal doses.
India's Ministry of Health and Family Welfare established the National Pharmacovigilance Programme (NPP) in 2004 to ensure that the benefits of medicine use outweigh the risks, thereby safeguarding the health of the Indian population. As India emerges as a global hub for generic drugs and clinical trials, monitoring ADRs across a large and diverse population poses significant challenges. A robust pharmacovigilance system is essential to identify and address potential drug-related issues.
Pharmacovigilance in Focus
The COVID-19 pandemic brought drug safety into the spotlight and increased public awareness of healthcare professionals’ and regulators’ roles, according to a study of global pharmacovigilance research indexed in Scopus from 2010 to 2020. Pharmacovigilance databases collect suspected adverse drug reaction reports from healthcare professionals, patients, companies, and regulators worldwide. VigiBase provides a global overview of medicine and vaccine safety, with access available to WHO Programme for International Drug Monitoring member organisations and, for a fee, to marketing authorisation holders, research organisations, software providers, and universities. However, one analysis questioned the overall value of social media data for pharmacovigilance because relevant posts were uncommon and coverage was low for many drugs.
Why is Pharmacovigilance Important?
In a country as vast and diverse as India, with its unique genetic variations, disease patterns, and healthcare practices, a standardized pharmacovigilance program is crucial. Collecting and analyzing data on drug safety allows for informed decisions about medication use. This information can lead to changes in drug labeling, warnings, precautions, or even the withdrawal of a drug from the market. It also helps educate healthcare providers about ADRs and informs official drug regulations.
- To monitor Adverse Drug Reactions (ADRs).
- To raise awareness among healthcare professionals about the importance of ADR reporting in India.
- To monitor the benefit-risk profile of medicines.
- To generate independent, evidence-based recommendations on the safety of medicines.
- To support the CDSCO in formulating safety-related regulatory decisions for medicines.
Research and New Methods
Springer’s Drug Safety and Pharmacovigilance research collection presents recent papers and news from researchers in the field. Nature’s corresponding collection highlights research, new methods, and ideas in drug safety and pharmacovigilance. Nature describes drug safety as concerning the potential for adverse effects associated with administering drugs, with efforts to establish a medicine’s safety profile beginning early in development, including in vitro work. A 2024 review emphasizes that continued innovation, collaboration, and commitment to drug safety will shape pharmacovigilance and improve patient outcomes.
Drug Safety and Pharmacovigilance
Drug safety generally focuses on monitoring and mitigating the potential risks and adverse effects of medicines. Pharmacovigilance is broader, encompassing the collection, analysis, and evaluation of safety information throughout a medicine’s lifecycle. One definition describes pharmacovigilance as the science and activities involved in detecting, assessing, understanding, and preventing adverse effects or other medicine- and vaccine-related problems, with an emphasis on proactive signal interpretation. Although the terms are often used interchangeably in industry and healthcare, the sources identify meaningful conceptual differences between them.
Moving Forward: Strengthening Pharmacovigilance
The study underscores the need to enhance pharmacovigilance awareness and practices among healthcare professionals in India. Improving ADR reporting through education, training, and simplified reporting processes is essential. By addressing these challenges, India can strengthen its drug safety monitoring systems and protect the health of its population.
Clinical Trial Reporting
Sponsors of clinical trials must submit reports of suspected unexpected serious adverse reactions to EudraVigilance. EudraVigilance is the electronic system used to manage and analyse information on suspected adverse reactions to medicines in the European Economic Area. This requirement connects clinical-trial safety reporting with a centralized system for ongoing analysis. It also places a specific reporting responsibility on trial sponsors during medicine development.
Persistent Systemic Challenges
Reported challenges in pharmacovigilance include changing regulatory processes and a lack of standardization in data systems used for evaluation. The field must also address the safety of herbal and combination medicines, as well as medicines for rare diseases. Another source notes that many adverse drug events go unreported or are reported incorrectly, limiting detection. The COVID-19 pandemic further highlighted the importance of pharmacovigilance and effective risk communication during public health emergencies.
Real-World Evidence and Accountability
Real-world data from electronic health records, patient registries, and social media are increasingly being integrated into pharmacovigilance strategies. These sources can help address limitations of traditional approaches and support safety surveillance across the clinical development lifecycle. Premarket clinical trials may have small sample sizes, restricted settings, and limited representation of specific populations, creating a role for real-world evidence in drug safety monitoring. Compliance failures in adverse-event reporting have also produced major fines in case studies involving Roche, GSK, and Abbott.